32 results on '"Terry C. Jones"'
Search Results
2. Detection of two alphaviruses: Middelburg virus and Sindbis virus from enzootic amplification cycles in southwestern Uganda
- Author
-
Selina Laura Graff, Georg Joachim Eibner, James Robert Ochieng, Terry C. Jones, Anthony Mutebi Nsubuga, Julius Julian Lutwama, Innocent Bidason Rwego, and Sandra Junglen
- Subjects
Middelburg virus ,Sindbis virus ,alphavirus ,Togaviridae ,arbovirus ,mosquito ,Microbiology ,QR1-502 - Abstract
Our knowledge of alphavirus genetic diversity is mainly based on viruses isolated from anthropophilic mosquito species, humans, and livestock during outbreaks. Studies on alphaviruses from sylvatic amplification cycles in sub-Saharan Africa have been conducted less often than from epizootic environments. To gain insight into alphavirus diversity in enzootic transmission cycles, we collected over 23,000 mosquitoes in lowland rainforest and savannah gallery forest in southwestern Uganda and tested them for alphavirus infections. We detected Sindbis virus (SINV) in a Culex Culex sp. mosquito and Middelburg virus (MIDV) in Eretmapodites intermedius and Mansonia africana. MIDV is a mosquito-borne alphavirus that causes febrile illness in sheep, goats, and horses and was previously not known to occur in Uganda. SINV, also a mosquito-borne alphavirus, causes mild infections in humans. Full genomes of SINV and MIDV were sequenced, showing a nucleotide identity of 99% to related strains. Both isolates replicated to high titres in a wide variety of vertebrate cells. Our data suggest endemic circulation of SINV and MIDV in Uganda.
- Published
- 2024
- Full Text
- View/download PDF
3. Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron
- Author
-
Simon Schröder, Anja Richter, Talitha Veith, Jackson Emanuel, Luca Gudermann, Kirstin Friedmann, Lara M. Jeworowski, Barbara Mühlemann, Terry C. Jones, Marcel A. Müller, Victor M. Corman, and Christian Drosten
- Subjects
COVID-19 ,SARS-CoV-2 ,Reverse genetics ,Virus fitness ,Antibody neutralization escape ,Spike protein evolution ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Intrinsic fitness costs are likely to have guided the selection of lineage-determining mutations during emergence of variants of SARS-CoV-2. Whereas changes in receptor affinity and antibody neutralization have been thoroughly mapped for individual mutations in spike, their influence on intrinsic replicative fitness remains understudied. Methods We analyzed mutations in immunodominant spike epitope E484 that became temporarily fixed over the pandemic. We engineered the resulting immune escape mutations E484K, -A, and -Q in recombinant SARS-CoV-2. We characterized viral replication, entry, and competitive fitness with and without immune serum from humans with defined exposure/vaccination history and hamsters monospecifically infected with the E484K variant. We additionally engineered a virus containing the Omicron signature mutations N501Y and Q498R that were predicted to epistatically enhance receptor binding. Results Multistep growth kinetics in Vero-, Calu-3, and NCI-H1299 were identical between viruses. Synchronized entry experiments based on cold absorption and temperature shift identified only an insignificant trend toward faster entry of the E484K variant. Competitive passage experiments revealed clear replicative fitness differences. In absence of immune serum, E484A and E484Q, but not E484K, were replaced by wildtype (WT) in competition assays. In presence of immune serum, all three mutants outcompeted WT. Decreased E484A fitness levels were over-compensated for by N501Y and Q498R, identifying a putative Omicron founder background that exceeds the intrinsic and effective fitness of WT and matches that of E484K. Critically, the E484A/Q498R/N501Y mutant and E484K have equal fitness also in presence of pre-Omicron vaccinee serum, whereas the fitness gain by E484K is lost in the presence of serum raised against the E484K variant in hamsters. Conclusions The emergence of E484A and E484Q prior to widespread population immunity may have been limited by fitness costs. In populations already exposed to the early immune escape epitope E484K, the Omicron founder background may have provided a basis for alternative immune escape evolution via E484A. Studies of major antigenic epitope changes with and without their epistatic context help reconstruct the sequential adjustments of intrinsic fitness versus neutralization escape during the evolution of major SARS-CoV-2 variants in an increasingly immune human population.
- Published
- 2023
- Full Text
- View/download PDF
4. Deep RNA sequencing of muscle tissue reveals absence of viral signatures in dermatomyositis
- Author
-
Victor M. Corman, Corinna Preusse, Julia Melchert, Olivier Benveniste, Randi Koll, Hans-Hilmar Goebel, Terry C. Jones, Christian Drosten, Ulrike Schara-Schmidt, Sarah Leonard-Louis, Werner Stenzel, and Josefine Radke
- Subjects
Dermatomyositis (DM) ,Interferon (IFN) ,Viral signature ,Next generation sequencing ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Objective: To explore a possible connection between active viral infections and manifestation of Dermatomyositis (DM). Methods: Skeletal muscle biopsies were analyzed from patients diagnosed with juvenile (n=10) and adult (n=12) DM. Adult DM patients harbored autoantibodies against either TIF-1γ (n=7) or MDA5 (n=5). Additionally, we investigated skeletal muscle biopsies from non-diseased controls (NDC, n=5). We used an unbiased high-throughput sequencing (HTS) approach to detect viral sequences. To further increase sequencing depth, a host depletion approach was applied. Results: In this observational study, no relevant viral sequences were detected either by native sequencing or after host depletion. The absence of detectable viral sequences makes an active viral infection of the muscle tissue unlikely to be the cause of DM in our cohorts. Discussion: Type I interferons (IFN) play a major role in the pathogenesis of both juvenile and adult dermatomyositis (DM). The IFN response is remarkably conserved between DM subtypes classified by specific autoantibodies. Certain acute viral infections are accompanied by a prominent type I IFN response involving similar downstream mechanisms as in DM. Aiming to elucidate the pathogenesis of DM in skeletal muscle tissue, we used an untargeted high-throughput sequencing and a host depletion approach to detect possible causative viruses.
- Published
- 2024
- Full Text
- View/download PDF
5. US National Institutes of Health Prioritization of SARS-CoV-2 Variants
- Author
-
Sam Turner, Arghavan Alisoltani, Debbie Bratt, Liel Cohen-Lavi, Bethany L. Dearlove, Christian Drosten, Will M. Fischer, Ron A.M. Fouchier, Ana Silvia Gonzalez-Reiche, Lukasz Jaroszewski, Zain Khalil, Eric LeGresley, Marc Johnson, Terry C. Jones, Barbara Mühlemann, David O’Connor, Mayya Sedova, Maulik Shukla, James Theiler, Zachary S. Wallace, Hyejin Yoon, Yun Zhang, Harm van Bakel, Marciela M. Degrace, Elodie Ghedin, Adam Godzik, Tomer Hertz, Bette Korber, Jacob Lemieux, Anna M. Niewiadomska, Diane J. Post, Morgane Rolland, Richard Scheuermann, and Derek J. Smith
- Subjects
COVID-19 ,2019 novel coronavirus disease ,coronavirus disease ,severe acute respiratory syndrome coronavirus 2 ,SARS-CoV-2 ,viruses ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
Since late 2020, SARS-CoV-2 variants have regularly emerged with competitive and phenotypic differences from previously circulating strains, sometimes with the potential to escape from immunity produced by prior exposure and infection. The Early Detection group is one of the constituent groups of the US National Institutes of Health National Institute of Allergy and Infectious Diseases SARS-CoV-2 Assessment of Viral Evolution program. The group uses bioinformatic methods to monitor the emergence, spread, and potential phenotypic properties of emerging and circulating strains to identify the most relevant variants for experimental groups within the program to phenotypically characterize. Since April 2021, the group has prioritized variants monthly. Prioritization successes include rapidly identifying most major variants of SARS-CoV-2 and providing experimental groups within the National Institutes of Health program easy access to regularly updated information on the recent evolution and epidemiology of SARS-CoV-2 that can be used to guide phenotypic investigations.
- Published
- 2023
- Full Text
- View/download PDF
6. Pathogen genomics study of an early medieval community in Germany reveals extensive co-infections
- Author
-
Joanna H. Bonczarowska, Julian Susat, Barbara Mühlemann, Isabelle Jasch-Boley, Sebastian Brather, Benjamin Höke, Susanne Brather-Walter, Valerie Schoenenberg, Jonathan Scheschkewitz, Gabriele Graenert, Dirk Krausse, Michael Francken, Terry C. Jones, Joachim Wahl, Almut Nebel, and Ben Krause-Kyora
- Subjects
Ancient DNA ,Pathogen genomics ,Ancient genomics ,Variola virus ,Smallpox ,Leprosy ,Biology (General) ,QH301-705.5 ,Genetics ,QH426-470 - Abstract
Abstract Background The pathogen landscape in the Early European Middle Ages remains largely unexplored. Here, we perform a systematic pathogen screening of the rural community Lauchheim “Mittelhofen,” in present-day Germany, dated to the Merovingian period, between fifth and eighth century CE. Skeletal remains of individuals were subjected to an ancient DNA metagenomic analysis. Genomes of the detected pathogens were reconstructed and analyzed phylogenetically. Results Over 30% of the individuals exhibit molecular signs of infection with hepatitis B virus (HBV), parvovirus B19, variola virus (VARV), and Mycobacterium leprae. Seven double and one triple infection were detected. We reconstructed four HBV genomes and one genome each of B19, VARV, and M. leprae. All HBV genomes are of genotype D4 which is rare in Europe today. The VARV strain exhibits a unique pattern of gene loss indicating that viruses with different gene compositions were circulating in the Early Middle Ages. The M. leprae strain clustered in branch 3 together with the oldest to-date genome from the UK. Conclusions The high burden of infectious disease, together with osteological markers of physiological stress, reflect a poor health status of the community. This could have been an indirect result of the climate decline in Europe at the time, caused by the Late Antique Little Ice Age (LALIA). Our findings suggest that LALIA may have created an ecological context in which persistent outbreaks set the stage for major epidemics of severe diseases such as leprosy and smallpox hundreds of years later.
- Published
- 2022
- Full Text
- View/download PDF
7. Genetic characterization of varicella-zoster and HIV-1 viruses from the cerebrospinal fluid of a co-infected encephalitic patient, Ghana
- Author
-
Philip El-Duah, Augustina Angelina Sylverken, Michael Owusu, Yaw Ampem Amoako, Richmond Yeboah, Richmond Gorman, Emmanuella Nyarko-Afriyie, Julia Schneider, Terry C. Jones, Joseph Bonney, Titus Adade, Eric Smart Yeboah, Tabea Binger, Victor Max Corman, Christian Drosten, and Richard Odame Phillips
- Subjects
Varicella-zoster virus ,Chickenpox ,HIV ,Coinfection ,Encephalitis ,Ghana ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Encephalitis is a serious disease of the brain characterized by prodromal and specific neurological symptoms. HIV infections offer opportunistic viruses, such as Varicella-zoster virus (VZV), the chance to cause encephalitis in patients. There is a lack of information on the genetic diversity of VZV in Ghana and other parts of Africa which requires sequencing and characterization studies to address. The active evolution of HIV-1 in West Africa also requires continuous surveillance for the emergence of new genetic forms. Case presentation VZV was detected in the CSF sample of an 11-year-old patient presenting with symptoms of encephalitis by real-time PCR diagnostics. To identify possible unknown aetiological pathogens, next-generation sequencing was performed, and revealed an HIV-1 co-infection. Alignments of concatenated HIV-1 genome fragments in the gag, pol, vif, env and nef regions and a near-complete VZV genome were analyzed by Bayesian inference, and phylogenetic trees were generated. The VZV sequence belongs to clade 5 and the HIV-1 sequence is a member of the CRF02_AG predominant circulating recombinant form in Ghana. Conclusions Diagnostic tests for CSF HIV would be useful where possible in patients presenting with encephalitis due to VZV and other opportunistic viruses in Kumasi to shed light on the role of HIV in encephalitis cases in Ghana. This report reaffirms the role of the CRF02_AG circulating recombinant form in HIV infections in Ghana and also gives a preliminary genetic characterization of VZV in Kumasi, Ghana.
- Published
- 2022
- Full Text
- View/download PDF
8. The International Virus Bioinformatics Meeting 2023
- Author
-
Franziska Hufsky, Ana B. Abecasis, Artem Babaian, Sebastian Beck, Liam Brierley, Simon Dellicour, Christian Eggeling, Santiago F. Elena, Udo Gieraths, Anh D. Ha, Will Harvey, Terry C. Jones, Kevin Lamkiewicz, Gabriel L. Lovate, Dominik Lücking, Martin Machyna, Luca Nishimura, Maximilian K. Nocke, Bernard Y. Renard, Shoichi Sakaguchi, Lygeri Sakellaridi, Jannes Spangenberg, Maria Tarradas-Alemany, Sandra Triebel, Yulia Vakulenko, Rajitha Yasas Wijesekara, Fernando González-Candelas, Sarah Krautwurst, Alba Pérez-Cataluña, Walter Randazzo, Gloria Sánchez, and Manja Marz
- Subjects
bioinformatics ,tools ,machine learning ,bacteriophages ,virus discovery ,virus classification ,Microbiology ,QR1-502 - Abstract
The 2023 International Virus Bioinformatics Meeting was held in Valencia, Spain, from 24–26 May 2023, attracting approximately 180 participants worldwide. The primary objective of the conference was to establish a dynamic scientific environment conducive to discussion, collaboration, and the generation of novel research ideas. As the first in-person event following the SARS-CoV-2 pandemic, the meeting facilitated highly interactive exchanges among attendees. It served as a pivotal gathering for gaining insights into the current status of virus bioinformatics research and engaging with leading researchers and emerging scientists. The event comprised eight invited talks, 19 contributed talks, and 74 poster presentations across eleven sessions spanning three days. Topics covered included machine learning, bacteriophages, virus discovery, virus classification, virus visualization, viral infection, viromics, molecular epidemiology, phylodynamic analysis, RNA viruses, viral sequence analysis, viral surveillance, and metagenomics. This report provides rewritten abstracts of the presentations, a summary of the key research findings, and highlights shared during the meeting.
- Published
- 2023
- Full Text
- View/download PDF
9. A Multicenter Clinical Diagnostic Accuracy Study of SureStatus, an Affordable, WHO Emergency Use-Listed, Rapid, Point-Of-Care Antigen-Detecting Diagnostic Test for SARS-CoV-2
- Author
-
Lisa J. Krüger, Andreas K. Lindner, Mary Gaeddert, Frank Tobian, Julian Klein, Salome Steinke, Federica Lainati, Paul Schnitzler, Olga Nikolai, Frank P. Mockenhaupt, Joachim Seybold, Victor M. Corman, Terry C. Jones, Nira R. Pollock, Britta Knorr, Andreas Welker, Stephan Weber, Nandini Sethurarnan, Jayanthi Swaminathan, Hilda Solomon, Ajay Padmanaban, Ma Thirunarayan, Prabakaran L, Margaretha de Vos, Stefano Ongarello, Jilian A. Sacks, Camille Escadafal, and Claudia M. Denkinger
- Subjects
SARS-CoV-2 ,COVID-19 ,antigen-detecting rapid diagnostic tests ,sensitivity ,specificity ,Microbiology ,QR1-502 - Abstract
ABSTRACT Access to reverse transcription-PCR (RT-PCR) testing, the gold standard for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection, is limited throughout the world, due to restricted resources, available infrastructure, and high costs. Antigen-detecting rapid diagnostic tests (Ag-RDTs) overcome some of these barriers, but independent clinical validations in settings of intended use are scarce. To inform the World Health Organization’s (WHO) emergency use listing (EUL) procedure and ensure affordable, high-quality Ag-RDTs, we assessed the performance and ease of use of the SureStatus for SARS-CoV-2. For this prospective, multicenter diagnostic accuracy study, we recruited unvaccinated participants with presumed SARS-CoV-2 infection in India and Germany from December 2020 to March 2021, when the Alpha (B.1.1.7) variant was predominantly circulating. Paired swabs were performed for (i) routine clinical RT-PCR testing (sampling was either nasopharyngeal [NP] or combined NP and oropharyngeal [NP/OP]) and (ii) Ag-RDT (sampling was NP). Performance of the Ag-RDT was compared to RT-PCR overall and by predefined subgroups, e.g., cycle threshold (CT) value, symptoms, and days from symptom onset. To understand the usability, a system usability scale (SUS) questionnaire and ease-of-use (EoU) assessment were performed. A total of 1,119 participants were included in the analysis, of whom 205 (18.3%) were RT-PCR positive. SureStatus detected 169 out of 205 RT-PCR-positive participants, reporting a sensitivity of 82.4% (95% confidence interval [CI]: 76.6% to 87.1%) and a specificity of 98.5% (95% CI: 97.4% to 99.1%). In the first 7 days post-symptom onset, the sensitivity was 90.7% (95% CI: 83.5% to 94.9%), when CT values were low and viral loads were high. The test was characterized as easy to use (SUS, 85/100) and considered suitable for point-of-care settings, although quality concerns were raised due to visibly contaminated packaging of swabs included in the test kits. The SureStatus diagnostic test can be considered a reliable test during the first week of SARS-CoV-2 infection, with high sensitivity in combination with excellent usability. IMPORTANCE Our manufacturer-independent, prospective diagnostic accuracy study assessed clinical performance in participants presumed to have a SARS-CoV-2 infection at three study sites in two countries. We assessed the accuracy overall and in predefined subgroups (CT values and symptom duration). SureStatus performed with high sensitivity. Its sensitivity was particularly high in the first 3 days after symptom onset and when CT values were low (i.e., the viral load was high). The system usability and ease-of-use assessment complements the accuracy assessment of the test and highlights critical factors to facilitate the widespread use of SureStatus in point-of-care settings. The high sensitivity demonstrated by the evaluated Ag-RDT within the first days of symptoms, when most transmission occurs, supports the role of Ag-RDTs for public health-relevant screening. Evidence from this study was used to inform the World Health Organization Emergency Use Listing procedure.
- Published
- 2022
- Full Text
- View/download PDF
10. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
- Author
-
Tatjana Schwarz, Pinkus Tober-Lau, David Hillus, Elisa T. Helbig, Lena J. Lippert, Charlotte Thibeault, Willi Koch, Irmgard Landgraf, Janine Michel, Leon Bergfeld, Daniela Niemeyer, Barbara Mühlemann, Claudia Conrad, Chantip Dang-Heine, Stefanie Kasper, Friederike Münn, Kai Kappert, Andreas Nitsche, Rudolf Tauber, Sein Schmidt, Piotr Kopankiewicz, Harald Bias, Joachim Seybold, Christof von Kalle, Terry C. Jones, Norbert Suttorp, Christian Drosten, Leif Erik Sander, Victor M. Corman, and Florian Kurth
- Subjects
vaccine ,mRNA ,immunity ,T cell ,B cell ,antibody ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
We detected delayed and reduced antibody and T-cell responses after BNT162b2 vaccination in 71 elderly persons (median age 81 years) compared with 123 healthcare workers (median age 34 years) in Germany. These data emphasize that nonpharmaceutical interventions for coronavirus disease remain crucial and that additional immunizations for the elderly might become necessary.
- Published
- 2021
- Full Text
- View/download PDF
11. Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021
- Author
-
Pinkus Tober-Lau, Tatjana Schwarz, David Hillus, Jana Spieckermann, Elisa T. Helbig, Lena J. Lippert, Charlotte Thibeault, Willi Koch, Leon Bergfeld, Daniela Niemeyer, Barbara Mühlemann, Claudia Conrad, Stefanie Kasper, Friederike Münn, Frank Kunitz, Terry C. Jones, Norbert Suttorp, Christian Drosten, Leif Erik Sander, Florian Kurth, and Victor M. Corman
- Subjects
vaccine ,mRNA ,outbreak ,phylogeny ,immunity ,T cell ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
One week after second vaccinations were administered, an outbreak of B.1.1.7 lineage severe acute respiratory syndrome coronavirus 2 infections occurred in a long-term care facility in Berlin, Germany, affecting 16/20 vaccinated and 4/4 unvaccinated residents. Despite considerable viral loads, vaccinated residents experienced mild symptoms and faster time to negative test results.
- Published
- 2021
- Full Text
- View/download PDF
12. SARS-CoV-2 Variant of Concern B.1.1.7: Diagnostic Sensitivity of Three Antigen-Detecting Rapid Tests
- Author
-
Andreas K. Lindner, Lisa J. Krüger, Olga Nikolai, Julian A. F. Klein, Heike Rössig, Paul Schnitzler, Victor M. Corman, Terry C. Jones, Frank Tobian, Mary Gaeddert, Susen Burock, Jilian A. Sacks, Joachim Seybold, Frank P. Mockenhaupt, and Claudia M. Denkinger
- Subjects
B.1.1.7 lineage ,COVID-19 ,SARS-CoV-2 ,antigen-detecting rapid test ,variants of concern ,Microbiology ,QR1-502 - Published
- 2022
- Full Text
- View/download PDF
13. Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7
- Author
-
Marek Widera, Barbara Mühlemann, Victor M. Corman, Tuna Toptan, Jörn Beheim-Schwarzbach, Niko Kohmer, Julia Schneider, Annemarie Berger, Talitha Veith, Christiane Pallas, Tobias Bleicker, Udo Goetsch, Julia Tesch, Rene Gottschalk, Terry C. Jones, Sandra Ciesek, and Christian Drosten
- Subjects
SARS-CoV-2 ,genetic diversity ,molecular surveillance ,B.1.1.7 ,natural selection ,spike mutation ,Biology (General) ,QH301-705.5 - Abstract
Background: International travel is a major driver of the introduction and spread of SARS-CoV-2. Aim: To investigate SARS-CoV-2 genetic diversity in the region of a major transport hub in Germany, we characterized the viral sequence diversity of the SARS-CoV-2 variants circulating in Frankfurt am Main, the city with the largest airport in Germany, from the end of October to the end of December 2020. Methods: In total, we recovered 136 SARS-CoV-2 genomes from nasopharyngeal swab samples. We isolated 104 isolates that were grown in cell culture and RNA from the recovered viruses and subjected them to full-genome sequence analysis. In addition, 32 nasopharyngeal swab samples were directly sequenced. Results and conclusion: We found 28 different lineages of SARS-CoV-2 circulating during the study period, including the variant of concern B.1.1.7 (Δ69/70, N501Y). Six of the lineages had not previously been observed in Germany. We detected the spike protein (S) deletion Δ69/Δ70 in 15% of all sequences, a four base pair (bp) deletion (in 2.9% of sequences) and a single bp deletion (in 0.7% of sequences) in ORF3a, leading to ORF3a truncations. In four sequences (2.9%), an amino acid deletion at position 210 in S was identified. In a single sample (0.7%), both a 9 bp deletion in ORF1ab and a 7 bp deletion in ORF7a were identified. One sequence in lineage B.1.1.70 had an N501Y substitution while lacking the Δ69/70 in S. The high diversity of sequences observed over two months in Frankfurt am Main highlights the persisting need for continuous SARS-CoV-2 surveillance using full-genome sequencing, particularly in cities with international airport connections.
- Published
- 2021
- Full Text
- View/download PDF
14. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis
- Author
-
Tatjana Schwarz, Carolin Otto, Terry C Jones, Florence Pache, Patrick Schindler, Moritz Niederschweiberer, Felix A Schmidt, Christian Drosten, Victor M Corman, Klemens Ruprecht, Jones, Terry C [0000-0003-1120-9531], Corman, Victor M [0000-0002-3605-0136], and Apollo - University of Cambridge Repository
- Subjects
COVID-19 Vaccines ,Multiple Sclerosis ,SARS-CoV-2 ,viruses ,T-Lymphocytes ,fungi ,Vaccination ,T cells ,virus diseases ,COVID-19 ,Antibodies, Viral ,anti-CD20 therapy ,Immunoglobulin A ,body regions ,Neurology ,Immunoglobulin G ,Spike Glycoprotein, Coronavirus ,antibodies ,Humans ,Neurology (clinical) ,skin and connective tissue diseases - Abstract
Background: Optimal management of anti-CD20-treated patients with multiple sclerosis (pwMS) is an important clinical task during the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Objectives: To characterize humoral and cellular immune responses to SARS-CoV-2 vaccinations/infections in a longitudinal cohort of anti-CD20 treated ( n = 175) and anti-CD20 therapy-naïve ( n = 41) pwMS. Methods: Anti-SARS-CoV-2 spike protein immunoglobulin G (IgG) and IgA, virus neutralizing capacity, IgG avidity and SARS-CoV-2-specific T cells were determined. Results: Following two SARS-CoV-2 vaccinations, not only SARS-CoV-2 spike protein IgG and IgA, but also neutralizing capacity and avidity of SARS-CoV-2 IgG were lower in anti-CD20-treated ( n = 51) than in anti-CD20 therapy-naïve pwMS ( n = 14) and in healthy controls (HC, n = 19). However, in all anti-CD20-treated pwMS vaccinated twice ( n = 26) or infected with SARS-CoV-2 ( n = 2), in whom SARS-CoV-2-specific T cells were measured, SARS-CoV-2-specific T cells were detectable, at levels similar to those of twice-vaccinated anti-CD20 therapy-naïve pwMS ( n = 7) and HC ( n = 19). SARS-CoV-2-S1 IgG levels ( r = 0.42, p = 0.002), antibody avidity ( r = 0.7, p Conclusions: These findings should inform treatment decisions and SARS-CoV-2 vaccination management in pwMS.
- Published
- 2022
15. Infectivity of an ancient hepatitis B virus cloned after retrieval from archaeological human remains
- Author
-
Tassilo Volz, Felix Lehmann, Nora Goldmann, Annika Volmari, Barbara Mühlemann, Christian Drosten, Terry C. Jones, Maura Dandri, and Dieter Glebe
- Published
- 2023
16. Non-structural genes of novel lemur adenoviruses reveal codivergence of virus and host
- Author
-
Talitha Veith, Tobias Bleicker, Monika Eschbach-Bludau, Sebastian Brünink, Barbara Mühlemann, Julia Schneider, Jörn Beheim-Schwarzbach, S Jacques Rakotondranary, Yedidya R Ratovonamana, Cedric Tsagnangara, Refaly Ernest, Faly Randriantafika, Simone Sommer, Nadine Stetter, Terry C Jones, Christian Drosten, Jörg U Ganzhorn, Victor M Corman, Veith, Talitha [0000-0002-0484-6332], Mühlemann, Barbara [0000-0002-5314-8530], Schneider, Julia [0000-0002-0494-1022], Sommer, Simone [0000-0002-5148-8136], Jones, Terry C [0000-0003-1120-9531], Corman, Victor M [0000-0002-3605-0136], and Apollo - University of Cambridge Repository
- Subjects
host-switch ,Virology ,prosimian ,adenovirus ,cospeciation ,primate ,Microbiology - Abstract
Adenoviruses (AdVs) are important human and animal pathogens and are frequently used as vectors for gene therapy and vaccine delivery. Surprisingly, there are only scant data regarding primate AdV origin and evolution, especially in the most basal primate hosts. We detect and sequence AdVs from faeces of two Madagascan lemur species. Complete genome sequence analyses define a new AdV species with a particularly large gene encoding a protein of unknown function in the early gene region 3. Unexpectedly, the new AdV species is not most similar to human or other simian AdVs but to bat adenovirus C. Genome characterisation shows signals of virus–host codivergence in non-structural genes, which show lower diversity than structural genes. Outside a lemur species mixing zone, recombination less frequently separates structural genes, as in human adenovirus C. The evolutionary history of lemur AdVs likely involves both a host switch and codivergence with the lemur hosts.
- Published
- 2023
17. Pharmacological inhibition of bromodomain and extra-terminal proteins induces NRF-2-mediated inhibition of SARS-CoV-2 replication and is subject to viral antagonism
- Author
-
Baxolele Mhlekude, Dylan Postmus, January Weiner, Saskia Stenzel, Francisco J. Zapatero-Belinchón, Ruth Olmer, Jenny Jansen, Anja Richter, Julian Heinze, Nicolas Heinemann, Barbara Mühlemann, Simon Schroeder, Terry C. Jones, Marcel Alexander Müller, Christian Drosten, Andreas Pich, Volker Thiel, Ulrich Martin, Daniela Niemeyer, Gisa Gerold, Dieter Beule, and Christine Goffinet
- Abstract
Inhibitors of bromodomain and extra-terminal proteins (iBETs), including JQ-1, have been suggested as potential therapeutics against SARS-CoV-2 infection. However, molecular mechanisms underlying JQ-1-induced antiviral activity and its susceptibility to viral antagonism remain incompletely understood. iBET treatment transiently inhibited infection by SARS-CoV-2 variants and SARS-CoV, but not MERS-CoV. Our functional assays confirmed JQ-1-mediated downregulation of ACE2 expression and multi-omics analysis uncovered induction of an antiviral NRF-2-mediated cytoprotective response as an additional antiviral component of JQ-1 treatment. Serial passaging of SARS-CoV-2 in the presence of JQ-1 resulted in predominance of ORF6-deficient variants. JQ-1 antiviral activity was transient in human bronchial airway epithelial cells (hBAECs) treated prior to infection and absent when administered therapeutically. We propose that JQ-1 exerts pleiotropic effects that collectively induce a transient antiviral state that is ultimately nullified by an established SARS-CoV-2 infection, raising questions on their clinical suitability in the context of COVID-19.
- Published
- 2022
18. Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™: An antigen-detecting point-of-care device for SARS-CoV-2
- Author
-
Federica Lainati, Paul Schnitzler, Nira R. Pollock, Claudia M. Denkinger, Lisa J. Krüger, Terry C. Jones, Margaretha de Vos, Christopher J. Neufeldt, Mary Gaeddert, Sarah Klemm, Victor M. Corman, Britta Knorr, Andreas K. Lindner, Ralf Bartenschlager, Berati Cerikan, Andreas Welker, Frank Tobian, Frank P. Mockenhaupt, Olga Nikolai, Julian A.F. Klein, Joachim Seybold, and Jilian A. Sacks
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Point-of-Care Systems ,Immunofluorescence ,Asymptomatic ,Diagnostic accuracy ,Sensitivity and Specificity ,law.invention ,Antigen ,law ,Internal medicine ,Medicine ,Humans ,Pandemics ,Polymerase chain reaction ,Point of care ,Detection limit ,Original Paper ,medicine.diagnostic_test ,business.industry ,SARS-CoV-2 ,COVID-19 ,General Medicine ,Infectious Diseases ,Antigen-detecting diagnostics ,Point-of-care ,RNA, Viral ,medicine.symptom ,business ,Viral load - Abstract
Purpose Rapid antigen-detecting tests (Ag-RDTs) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can transform pandemic control. Thus far, sensitivity (≤ 85%) of lateral-flow assays has limited scale-up. Conceivably, microfluidic immunofluorescence Ag-RDTs could increase sensitivity for SARS-CoV-2 detection. Methods This multi-centre diagnostic accuracy study investigated performance of the microfluidic immunofluorescence LumiraDx™ assay, enrolling symptomatic and asymptomatic participants with suspected SARS-CoV-2 infection. Participants collected a supervised nasal mid-turbinate (NMT) self-swab for Ag-RDT testing, in addition to a professionally collected nasopharyngeal (NP) swab for routine testing with reverse transcriptase polymerase chain reaction (RT-PCR). Results were compared to calculate sensitivity and specificity. Sub-analyses investigated the results by viral load, symptom presence and duration. An analytical study assessed exclusivity and limit-of-detection (LOD). In addition, we evaluated ease-of-use. Results The study was conducted between November 2nd 2020 and 4th of December 2020. 761 participants were enrolled, with 486 participants reporting symptoms on testing day. 120 out of 146 RT-PCR positive cases were detected positive by LumiraDx™, resulting in a sensitivity of 82.2% (95% CI 75.2–87.5%). Specificity was 99.3% (CI 98.3–99.7%). Sensitivity was increased in individuals with viral load ≥ 7 log10 SARS-CoV2 RNA copies/ml (93.8%; CI 86.2–97.3%). Testing against common respiratory commensals and pathogens showed no cross-reactivity and LOD was estimated to be 2–56 PFU/mL. The ease-of-use-assessment was favourable for lower throughput settings. Conclusion The LumiraDx™ assay showed excellent analytical sensitivity, exclusivity and clinical specificity with good clinical sensitivity using supervised NMT self-sampling. Trial registration number and registration date DRKS00021220 and 01.04.2020
- Published
- 2021
19. Genetic variability, including gene duplication and deletion, in early sequences from the 2022 European monkeypox outbreak
- Author
-
Terry C. Jones, Julia Schneider, Barbara Mühlemann, Talitha Veith, Jörn Beheim-Schwarzbach, Julia Tesch, Marie Luisa Schmidt, Felix Walper, Tobias Bleicker, Caroline Isner, Frieder Pfäfflin, Ricardo Niklas Werner, Victor M. Corman, and Christian Drosten
- Abstract
Genome sequences from 47 monkeypox virus infections detected in a German university virology laboratory were analyzed in context of other sequences from the 2022 outbreak and earlier monkeypox genomes. Identical non-synonymous amino acid changes in six genes and the signature of APOBEC editing match other sequences from the European outbreak. Non-synonymous changes that were present in one to three sequences were found in 34 other genes. In sequences from two lesions of one patient, an 856 nucleotide translocation between genome termini resulted in the duplication of an initial 5’ gene, and the disruption or complete deletion of four genes near the 3’ genome end. Orthopoxvirus genome rearrangements of this nature are known to confer fitness advantages in the face of selection pressure. This change may therefore represent an early virus adaptation in the novel widespread and sustained human-to-human context of the current monkeypox outbreak.
- Published
- 2022
20. 90K/LGALS3BP Expression is Upregulated in COVID-19 but Does Not Restrict SARS-CoV-2 Infection
- Author
-
Laure Bosquillon de Jarcy, Bengisu Akbil, Johanna Leyens, Dylan Postmus, Greta Harnisch, Jenny Jansen, Marie L. Schmidt, Annette Aigner, Fabian Pott, Robert Lorenz Chua, Lilian Krist, Roberta Gentile, Barbara Mühlemann, Terry C. Jones, Daniela Niemeyer, Julia Fricke, Thomas Keil, Tobias Pischon, Jürgen Janke, Christian Conrad, Stefano Iacobelli, Christian Drosten, Victor M. Corman, Markus Ralser, Roland Eils, Florian Kurth, Leif Sander, and Christine Goffinet
- Abstract
Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients. 90K protein serum levels were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties.
- Published
- 2022
21. Mapping SARS-CoV-2 antigenic relationships and serological responses
- Author
-
Samuel H. Wilks, Barbara Mühlemann, Xiaoying Shen, Sina Türeli, Eric B. LeGresley, Antonia Netzl, Miguela A. Caniza, Jesus N. Chacaltana-Huarcaya, Victor M. Corman, Xiaoju Daniell, Michael B. Datto, Fatimah S. Dawood, Thomas N. Denny, Christian Drosten, Ron A. M. Fouchier, Patricia J. Garcia, Peter J. Halfmann, Agatha Jassem, Lara M. Jeworowski, Terry C. Jones, Yoshihiro Kawaoka, Florian Krammer, Charlene McDanal, Rolando Pajon, Viviana Simon, Melissa S. Stockwell, Haili Tang, Harm van Bakel, Vic Veguilla, Richard Webby, David C. Montefiori, and Derek J. Smith
- Subjects
Article - Abstract
During the SARS-CoV-2 pandemic, multiple variants with differing amounts of escape from pre-existing immunity have emerged, causing concerns about continued protection. Here, we use antigenic cartography to quantify and visualize the antigenic relationships among 16 SARS-CoV-2 variants titrated against serum samples taken post-vaccination and post-infection with seven different variants. We find major antigenic differences caused by substitutions at spike positions 417, 452, 484, and possibly 501. B.1.1.529 (Omicron BA.1) showed the highest escape from all sera tested. Visualization of serological responses as antibody landscapes shows how reactivity clusters in different regions of antigenic space. We find changes in immunodominance of different spike regions depending on the variant an individual was exposed to, with implications for variant risk assessment and vaccine strain selection.One sentence summaryAntigenic Cartography of SARS-CoV-2 variants reveals amino acid substitutions governing immune escape and immunodominance patterns.
- Published
- 2022
22. Defining the risk of SARS-CoV-2 variants on immune protection
- Author
-
Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, Florian Krammer, Alba Grifoni, Arghavan Alisoltani, Galit Alter, Rama R. Amara, Ralph S. Baric, Dan H. Barouch, Jesse D. Bloom, Louis-Marie Bloyet, Gaston Bonenfant, Adrianus C. M. Boon, Eli A. Boritz, Debbie L. Bratt, Traci L. Bricker, Liliana Brown, William J. Buchser, Juan Manuel Carreño, Liel Cohen-Lavi, Tamarand L. Darling, Meredith E. Davis-Gardner, Bethany L. Dearlove, Han Di, Meike Dittmann, Nicole A. Doria-Rose, Daniel C. Douek, Christian Drosten, Venkata-Viswanadh Edara, Ali Ellebedy, Thomas P. Fabrizio, Guido Ferrari, Will M. Fischer, William C. Florence, Ron A. M. Fouchier, John Franks, Adolfo García-Sastre, Adam Godzik, Ana Silvia Gonzalez-Reiche, Aubree Gordon, Bart L. Haagmans, Peter J. Halfmann, David D. Ho, Michael R. Holbrook, Yaoxing Huang, Sarah L. James, Lukasz Jaroszewski, Trushar Jeevan, Robert M. Johnson, Terry C. Jones, Astha Joshi, Yoshihiro Kawaoka, Lisa Kercher, Marion P. G. Koopmans, Bette Korber, Eilay Koren, Richard A. Koup, Eric B. LeGresley, Jacob E. Lemieux, Mariel J. Liebeskind, Zhuoming Liu, Brandi Livingston, James P. Logue, Yang Luo, Adrian B. McDermott, Margaret J. McElrath, Victoria A. Meliopoulos, Vineet D. Menachery, David C. Montefiori, Barbara Mühlemann, Vincent J. Munster, Jenny E. Munt, Manoj S. Nair, Antonia Netzl, Anna M. Niewiadomska, Sijy O’Dell, Andrew Pekosz, Stanley Perlman, Marjorie C. Pontelli, Barry Rockx, Morgane Rolland, Paul W. Rothlauf, Sinai Sacharen, Richard H. Scheuermann, Stephen D. Schmidt, Michael Schotsaert, Stacey Schultz-Cherry, Robert A. Seder, Mayya Sedova, Alessandro Sette, Reed S. Shabman, Xiaoying Shen, Pei-Yong Shi, Maulik Shukla, Viviana Simon, Spencer Stumpf, Nancy J. Sullivan, Larissa B. Thackray, James Theiler, Paul G. Thomas, Sanja Trifkovic, Sina Türeli, Samuel A. Turner, Maria A. Vakaki, Harm van Bakel, Laura A. VanBlargan, Leah R. Vincent, Zachary S. Wallace, Li Wang, Maple Wang, Pengfei Wang, Wei Wang, Scott C. Weaver, Richard J. Webby, Carol D. Weiss, David E. Wentworth, Stuart M. Weston, Sean P. J. Whelan, Bradley M. Whitener, Samuel H. Wilks, Xuping Xie, Baoling Ying, Hyejin Yoon, Bin Zhou, Tomer Hertz, Derek J. Smith, Michael S. Diamond, Diane J. Post, Mehul S. Suthar, Ghedin, Elodie [0000-0002-1515-725X], Frieman, Matthew B [0000-0003-0107-0775], Krammer, Florian [0000-0003-4121-776X], Grifoni, Alba [0000-0002-2209-5966], Alter, Galit [0000-0002-7680-9215], Amara, Rama R [0000-0002-6309-6797], Baric, Ralph S [0000-0001-6827-8701], Barouch, Dan H [0000-0001-5127-4659], Bloom, Jesse D [0000-0003-1267-3408], Bloyet, Louis-Marie [0000-0002-5648-3190], Boon, Adrianus CM [0000-0002-4700-8224], Bratt, Debbie L [0000-0002-5822-5558], Buchser, William J [0000-0002-6675-6359], Cohen-Lavi, Liel [0000-0001-6909-4779], Dearlove, Bethany L [0000-0003-3653-4592], Drosten, Christian [0000-0001-7923-0519], Edara, Venkata-Viswanadh [0000-0001-9321-7839], Ellebedy, Ali [0000-0002-6129-2532], Fabrizio, Thomas P [0000-0002-8960-0728], Fouchier, Ron AM [0000-0001-8095-2869], García-Sastre, Adolfo [0000-0002-6551-1827], Godzik, Adam [0000-0002-2425-852X], Gonzalez-Reiche, Ana Silvia [0000-0003-3583-4497], Gordon, Aubree [0000-0002-9352-7877], Haagmans, Bart L [0000-0001-6221-2015], Ho, David D [0000-0003-1627-149X], Holbrook, Michael R [0000-0002-0824-2667], Huang, Yaoxing [0000-0001-6270-1644], James, Sarah L [0000-0002-6969-1167], Johnson, Robert M [0000-0002-1976-7688], Jones, Terry C [0000-0003-1120-9531], Joshi, Astha [0000-0003-4914-8228], Kawaoka, Yoshihiro [0000-0001-5061-8296], Kercher, Lisa [0000-0001-6300-0452], Koopmans, Marion PG [0000-0002-5204-2312], Korber, Bette [0000-0002-2026-5757], LeGresley, Eric B [0000-0002-5286-5693], Liebeskind, Mariel J [0000-0003-4595-0651], Liu, Zhuoming [0000-0001-8198-0976], Logue, James P [0000-0002-7410-9741], Luo, Yang [0000-0003-3277-8792], McDermott, Adrian B [0000-0003-0616-9117], Meliopoulos, Victoria A [0000-0003-1442-9177], Menachery, Vineet D [0000-0001-8803-7606], Munster, Vincent J [0000-0002-2288-3196], Nair, Manoj S [0000-0002-5994-3957], Netzl, Antonia [0000-0001-8034-2382], Pekosz, Andrew [0000-0003-3248-1761], Perlman, Stanley [0000-0003-4213-2354], Rockx, Barry [0000-0003-2463-027X], Rolland, Morgane [0000-0003-3650-8490], Rothlauf, Paul W [0000-0002-0941-4467], Scheuermann, Richard H [0000-0003-1355-892X], Schotsaert, Michael [0000-0003-3156-3132], Schultz-Cherry, Stacey [0000-0002-2021-727X], Seder, Robert A [0000-0003-3133-0849], Shabman, Reed S [0000-0003-3272-3484], Shi, Pei-Yong [0000-0001-5553-1616], Simon, Viviana [0000-0002-6416-5096], Thackray, Larissa B [0000-0002-9380-6569], Thomas, Paul G [0000-0001-7955-0256], Trifkovic, Sanja [0000-0002-0710-9514], Türeli, Sina [0000-0001-7342-9295], van Bakel, Harm [0000-0002-1376-6916], VanBlargan, Laura A [0000-0002-8922-8946], Vincent, Leah R [0000-0001-9262-1813], Wallace, Zachary S [0000-0003-0237-501X], Wang, Pengfei [0000-0003-2454-7652], Weaver, Scott C [0000-0001-8016-8556], Webby, Richard J [0000-0002-4397-7132], Weiss, Carol D [0000-0002-9965-1289], Wentworth, David E [0000-0002-5190-980X], Weston, Stuart M [0000-0001-9840-2953], Whelan, Sean PJ [0000-0003-1564-8590], Whitener, Bradley M [0000-0001-6652-0701], Xie, Xuping [0000-0003-0918-016X], Yoon, Hyejin [0000-0002-3344-9096], Hertz, Tomer [0000-0002-0561-1578], Smith, Derek J [0000-0002-2393-1890], Diamond, Michael S [0000-0002-8791-3165], Post, Diane J [0000-0003-3890-9116], Suthar, Mehul S [0000-0002-2686-8380], and Apollo - University of Cambridge Repository
- Subjects
Multidisciplinary ,COVID-19 Vaccines ,Pharmacogenomic Variants ,Virulence ,SARS-CoV-2 ,COVID-19 ,Biological Evolution ,Article ,United States ,SDG 3 - Good Health and Well-being ,National Institute of Allergy and Infectious Diseases (U.S.) ,Animals ,Humans ,Pandemics - Abstract
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced following infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH) established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) program. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants potentially impacting transmission, virulence, and resistance to convalescent and vaccine-induced immunity. The SAVE program serves as a critical data-generating component of the United States Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines, and therapeutics and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity, and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.
- Published
- 2022
23. Autochthonous West Nile virus infection in Germany: Increasing numbers and a rare encephalitis case in a kidney transplant recipient
- Author
-
Klemens Ruprecht, Christian Drosten, Mira Choi, Marie Luisa Schmidt, Terry C. Jones, Julia Schneider, Dirk Werber, Friederike Bachmann, Leon Bergfeld, Victor M. Corman, Kai-Uwe Eckardt, Marta Zuchowski, Lille Kurvits, Jörg Hofmann, Iris Meier, Zuchowski, Marta [0000-0003-3786-8033], Corman, Victor Max [0000-0002-3605-0136], and Apollo - University of Cambridge Repository
- Subjects
Adult ,viruses ,encephalitis ,Disease ,Asymptomatic ,Article ,Serology ,Germany ,Pandemic ,medicine ,diagnostics ,Humans ,emerging disease ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Meningoencephalitis ,virus diseases ,General Medicine ,medicine.disease ,Virology ,Kidney Transplantation ,Kidney transplant recipient ,arboviruses ,medicine.symptom ,business ,Meningitis ,West Nile virus ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,Encephalitis ,West Nile Fever - Abstract
West Nile Virus (WNV) infections are increasingly detected in birds and horses in central Europe, with a first mosquito-borne autochthonous human infection detected in Germany in 2019. Human infections are typically asymptomatic, with occasional severe neurological disease. Because of a low number of cases in central Europe, awareness regarding potential cases is low and WNV diagnostic is neglected. We tested cerebrospinal fluid (CSF) samples from unsolved encephalitis and meningitis cases from Berlin from 2019 and 2020, and describe a WNV-encephalitis case in a 33-year old kidney transplant recipient. The infectious course was resolved by serology, RT-PCR, and sequencing of stored samples. Phylogenetic sequence analysis revealed a close relationship of the patient's WNV strain to German sequences from 2019 and 2020. A lack of travel history and patient self-isolation during the SARS-CoV-2 pandemic suggest the infection was acquired in the patient's home or garden. Serological tests of four people sharing the living space were negative. Retrospective RT-PCR and WNV-IgM testing of 671 CSF samples from unsolved encephalitis and meningitis cases from Berlin detected no additional infections. The recent increase of WNV cases illustrates the importance of considering WNV in cases of meningoencephalitis, especially in immunocompromised patients, as described here. Proper education and communication and a revised diagnostic strategy will help to raise awareness and to detect future WNV infections. This article is protected by copyright. All rights reserved.
- Published
- 2022
- Full Text
- View/download PDF
24. A Multi-Center Clinical Diagnostic Accuracy Study of Surestatus - an Affordable, WHO Emergency-Use-Listed, Rapid, Point-of-Care, Antigen-Detecting Diagnostic Test for SARS-CoV-2
- Author
-
Lisa Johanna Krüger, Andreas K. Lindner, Mary Gaeddert, Frank Tobian, Julian Klein, Salome Steinke, Federica Lainati, Paul Schnitzler, Olga Nikolai, Frank P. Mockenhaupt, Joachim Seybold, Victor M. Corman, Terry C. Jones, Nira R. Pollock, Britta Knorr, Andreas Welker, Stephan Weber, Nandini Sethurarnan, Jayanthi Swaminathan, Hilda Solomon, Ajay Padmanaban, Ma Thirunarayan, L Prabakaran, Margaretha de Vos, Stefano Ongarello, Jilian A. Sacks, Camille Escadafal, and Claudia Denkinger
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
25. SARS-CoV-2 Rapid Antigen Test Sensitivity and Viral Load in Freshly Symptomatic Hospital Employees, December 2020 to February 2022
- Author
-
Leonie Meiners, Johanna Horn, Barbara Mühlemann, Marie Luisa Schmidt, Felix Walper, Peter Menzel, Rolf Schwarzer, Ruben Rose, Andi Krumbholz, Terry C. Jones, Victor M. Corman, Joachim Seybold, and Christian Drosten
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
26. SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression
- Author
-
Daniela Niemeyer, Saskia Stenzel, Talitha Veith, Simon Schroeder, Kirstin Friedmann, Friderike Weege, Jakob Trimpert, Julian Heinze, Anja Richter, Jenny Jansen, Jackson Emanuel, Julia Kazmierski, Fabian Pott, Lara M. Jeworowski, Ruth Olmer, Mark-Christian Jaboreck, Beate Tenner, Jan Papies, Felix Walper, Marie L. Schmidt, Nicolas Heinemann, Elisabeth Möncke-Buchner, Morris Baumgardt, Karen Hoffmann, Marek Widera, Tran Thi Nhu Thao, Anita Balázs, Jessica Schulze, Christin Mache, Terry C. Jones, Markus Morkel, Sandra Ciesek, Leif G. Hanitsch, Marcus A. Mall, Andreas C. Hocke, Volker Thiel, Klaus Osterrieder, Thorsten Wolff, Ulrich Martin, Victor M. Corman, Marcel A. Müller, Christine Goffinet, Christian Drosten, and Publica
- Subjects
General Immunology and Microbiology ,630 Agriculture ,SARS-CoV-2 ,General Neuroscience ,Humans ,COVID-19 ,610 Medicine & health ,Angiotensin-Converting Enzyme 2 ,General Agricultural and Biological Sciences ,Antibodies, Blocking ,General Biochemistry, Genetics and Molecular Biology ,Virus Shedding - Abstract
Epidemiological data demonstrate that Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) Alpha and Delta are more transmissible, infectious, and pathogenic than previous variants. Phenotypic properties of VOC remain understudied. Here, we provide an extensive functional study of VOC Alpha replication and cell entry phenotypes assisted by reverse genetics, mutational mapping of spike in lentiviral pseudotypes, viral and cellular gene expression studies, and infectivity stability assays in an enhanced range of cell and epithelial culture models. In almost all models, VOC Alpha spread less or equally efficiently as ancestral (B.1) SARS-CoV-2. B.1. and VOC Alpha shared similar susceptibility to serum neutralization. Despite increased relative abundance of specific sgRNAs in the context of VOC Alpha infection, immune gene expression in infected cells did not differ between VOC Alpha and B.1. However, inferior spreading and entry efficiencies of VOC Alpha corresponded to lower abundance of proteolytically cleaved spike products presumably linked to the T716I mutation. In addition, we identified a bronchial cell line, NCI-H1299, which supported 24-fold increased growth of VOC Alpha and is to our knowledge the only cell line to recapitulate the fitness advantage of VOC Alpha compared to B.1. Interestingly, also VOC Delta showed a strong (595-fold) fitness advantage over B.1 in these cells. Comparative analysis of chimeric viruses expressing VOC Alpha spike in the backbone of B.1, and vice versa, showed that the specific replication phenotype of VOC Alpha in NCI-H1299 cells is largely determined by its spike protein. Despite undetectable ACE2 protein expression in NCI-H1299 cells, CRISPR/Cas9 knock-out and antibody-mediated blocking experiments revealed that multicycle spread of B.1 and VOC Alpha required ACE2 expression. Interestingly, entry of VOC Alpha, as opposed to B.1 virions, was largely unaffected by treatment with exogenous trypsin or saliva prior to infection, suggesting enhanced resistance of VOC Alpha spike to premature proteolytic cleavage in the extracellular environment of the human respiratory tract. This property may result in delayed degradation of VOC Alpha particle infectivity in conditions typical of mucosal fluids of the upper respiratory tract that may be recapitulated in NCI-H1299 cells closer than in highly ACE2-expressing cell lines and models. Our study highlights the importance of cell model evaluation and comparison for in-depth characterization of virus variant-specific phenotypes and uncovers a fine-tuned interrelationship between VOC Alpha- and host cell-specific determinants that may underlie the increased and prolonged virus shedding detected in patients infected with VOC Alpha.
- Published
- 2021
27. Virological assessment of hospitalized patients with COVID-2019
- Author
-
Roman, Wölfel, Victor M, Corman, Wolfgang, Guggemos, Michael, Seilmaier, Sabine, Zange, Marcel A, Müller, Daniela, Niemeyer, Terry C, Jones, Patrick, Vollmar, Camilla, Rothe, Michael, Hoelscher, Tobias, Bleicker, Sebastian, Brünink, Julia, Schneider, Rosina, Ehmann, Katrin, Zwirglmaier, Christian, Drosten, and Clemens, Wendtner
- Subjects
Pneumonia, Viral ,Urine ,Antibodies, Viral ,Virus Replication ,Polymorphism, Single Nucleotide ,Betacoronavirus ,Coronavirus Envelope Proteins ,Feces ,COVID-19 Testing ,Viral Envelope Proteins ,Humans ,Lung ,Pandemics ,Base Sequence ,Clinical Laboratory Techniques ,SARS-CoV-2 ,Sputum ,COVID-19 ,Viral Load ,Virus Shedding ,Hospitalization ,Blood ,Immunoglobulin M ,Seroconversion ,Immunoglobulin G ,Pharynx ,RNA, Viral ,Coronavirus Infections - Abstract
Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 2019
- Published
- 2020
28. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study
- Author
-
Barbara Mühlemann, Charlotte Thibeault, David Hillus, Elisa T. Helbig, Lena J. Lippert, Pinkus Tober-Lau, Tatjana Schwarz, Marcel A. Müller, Martin Witzenrath, Norbert Suttorp, Leif E. Sander, Christian Drosten, Terry C. Jones, Victor M. Corman, Florian Kurth, Stefan Hippenstiel, Sascha S. Haenel, Mirja Mittermaier, Fridolin Steinbeis, Tilman Lingscheid, Bettina Temmesfeld-Wollbrück, Thomas Zoller, Holger Müller-Redetzky, Alexander Uhrig, Daniel Grund, Christoph Ruwwe-Glösenkamp, Miriam S. Stegemann, Katrin M. Heim, Ralf H. Hübner, Bastian Opitz, Kai-Uwe Eckardt, Martin Möckel, Felix Balzer, Claudia Spies, Steffen Weber-Carstens, Frank Tacke, Chantip Dang-Heine, Michael Hummel, Georg Schwanitz, Uwe D. Behrens, Maria Rönnefarth, Sein Schmidt, Alexander Krannich, Christof von Kalle, Linda Jürgens, Malte Kleinschmidt, Sophy Denker, Moritz Pfeiffer, Belén Millet Pascual-Leone, Luisa Mrziglod, Felix Machleidt, Sebastian Albus, Felix Bremer, Jan-Moritz Doehn, Tim Andermann, Carmen Garcia, Philipp Knape, Philipp M. Krause, Liron Lechtenberg, Yaosi Li, Panagiotis Pergantis, Till Jacobi, Teresa Ritter, Berna Yedikat, Lennart Pfannkuch, Christian Zobel, Ute Kellermann, Susanne Fieberg, Laure Bosquillon de Jarcy, Anne Wetzel, Christoph Tabeling, Markus C. Brack, Moritz Müller-Plathe, Jan M. Kruse, Daniel Zickler, Andreas Edel, Britta Stier, Roland Körner, Nils B. Müller, Philipp Enghard, Paula Stubbemann, Nadine Olk, Willi M. Koch, Alexandra Horn, Katrin K. Stoyanova, Saskia Zvorc, Lucie Kretzler, Lil A. Meyer-Arndt, Linna Li, Isabelle Wirsching, Denise Treue, Dana Briesemeister, Jenny Schlesinger, Birgit Sawitzki, Lara Bardtke, Kai Pohl, Philipp Georg, Daniel Wendisch, Anna L. Hiller, Sophie Brumhard, Marie Luisa Schmidt, Leonie Meiners, and Patricia Tscheak
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Respiratory System ,030106 microbiology ,Anti-Inflammatory Agents ,Antibodies, Viral ,Gastroenterology ,Dexamethasone ,Virus ,03 medical and health sciences ,COVID-19 Nucleic Acid testing ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Seroconversion ,Antibody ,Viral concentration ,biology ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,General Medicine ,Viral Load ,Immunoglobulin A ,COVID-19 Drug Treatment ,Hospitalization ,Research Note ,Kinetics ,Infectious Diseases ,medicine.anatomical_structure ,Immunoglobulin G ,biology.protein ,RNA, Viral ,Observational study ,business ,Viral load ,medicine.drug ,Respiratory tract - Abstract
Objectives Dexamethasone has become the standard of care for severe coronavirus disease 2019 (COVID-19), but its virological impact is poorly understood. The objectives of this work were to characterize the kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) concentration in the upper respiratory tract (URT) and the antibody response in patients with (D+) and without (D–) dexamethasone treatment. Methods Data and biosamples from hospitalized patients with severe COVID-19, enrolled between 4th March and 11th December 2020 in a prospective observational study, were analysed. SARS-CoV-2 virus concentration in serial URT samples was measured using RT-PCR. SARS-CoV-2-specific immunoglobulins A and G (IgA and IgG) were measured in serum samples using S1-ELISA. Results We compared 101 immunocompetent patients who received dexamethasone (according to the inclusion criteria and dosage determined in the RECOVERY trial) to 93 immunocompetent patients with comparable disease severity from the first months of the pandemic, who had not been treated with dexamethasone or other glucocorticoids. We found no inter-group differences in virus concentration kinetics, duration of presence of viral loads >106 viral copies/mL (D+ median 17 days (IQR 13–24), D– 19 days (IQR 13–29)), or time from symptom onset until seroconversion (IgA: D+ median 11.5 days (IQR 11–12), D– 14 days (IQR 11.5–15.75); IgG: D+ 13 days (IQR 12–14.5), D– 12 days (IQR 11–15)). Conclusion Dexamethasone does not appear to lead to a change in virus clearance or a delay in antibody response in immunocompetent patients hospitalized with severe COVID-19.
- Published
- 2021
29. Mutations, drift, and the influenza archipelago
- Author
-
Derek J, Smith, Alan S, Lapedes, Jan C, de Jong, Theo M, Bestebroer, Terry C, Jones, Guus F, Rimmelzwaan, Albert D M E, Osterhaus, and Ron A M, Fouchier
- Abstract
Extract: Annual influenza (flu) epidemics in humans affect 5-15% of the population, causing an estimated half million deaths worldwide per year. Antibodies against the viral surface glycoprotein hemagglutinin (HA) provide protective immunity to influenza virus infection and this protein is therefore the primary component of influenza vaccines. However, the antigenic structure of HA has changed significantly over time, a process known as antigenic drift. In as many years, antigenic drift necessitates an update of the influenza vaccine to ensure sufficient efficacy against newly emerging virus variants. Antigenic drift is therefore both the root cause of the enormous public health burden of influenza epidemics, and a primary reason why the virus is such a fascinating pathogen from a scientific perspective. Thousands of influenza viruses are isolated and analyzed each year by the national and international laboratories that form the World Health Organization (WHO) global influenza surveillance network. This worldwide surveillance effort produces the data for the twice-yearly vaccine strain selection meetings, and has resulted in the establishment of a remarkable historical record of the global evolution of this important pathogen. The degree to which immunity induced by one strain is effective against another is mostly dependent on the extent of the antigenic difference between the strains. The analysis of antigenic differences between strains is therefore critical for surveillance and vaccine strain selection, and is also a cornerstone of basic and applied research in virology.
- Published
- 2010
30. Pharmacological inhibition of bromodomain and extra-terminal proteins induces an NRF-2-mediated antiviral state that is subverted by SARS-CoV-2 infection.
- Author
-
Baxolele Mhlekude, Dylan Postmus, Saskia Stenzel, January Weiner, Jenny Jansen, Francisco J Zapatero-Belinchón, Ruth Olmer, Anja Richter, Julian Heinze, Nicolas Heinemann, Barbara Mühlemann, Simon Schroeder, Terry C Jones, Marcel A Müller, Christian Drosten, Andreas Pich, Volker Thiel, Ulrich Martin, Daniela Niemeyer, Gisa Gerold, Dieter Beule, and Christine Goffinet
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
Inhibitors of bromodomain and extra-terminal proteins (iBETs), including JQ-1, have been suggested as potential prophylactics against SARS-CoV-2 infection. However, molecular mechanisms underlying JQ-1-mediated antiviral activity and its susceptibility to viral subversion remain incompletely understood. Pretreatment of cells with iBETs inhibited infection by SARS-CoV-2 variants and SARS-CoV, but not MERS-CoV. The antiviral activity manifested itself by reduced reporter expression of recombinant viruses, and reduced viral RNA quantities and infectious titers in the culture supernatant. While we confirmed JQ-1-mediated downregulation of expression of angiotensin-converting enzyme 2 (ACE2) and interferon-stimulated genes (ISGs), multi-omics analysis addressing the chromatin accessibility, transcriptome and proteome uncovered induction of an antiviral nuclear factor erythroid 2-related factor 2 (NRF-2)-mediated cytoprotective response as an additional mechanism through which JQ-1 inhibits SARS-CoV-2 replication. Pharmacological inhibition of NRF-2, and knockdown of NRF-2 and its target genes reduced JQ-1-mediated inhibition of SARS-CoV-2 replication. Serial passaging of SARS-CoV-2 in the presence of JQ-1 resulted in predominance of ORF6-deficient variant, which exhibited resistance to JQ-1 and increased sensitivity to exogenously administered type I interferon (IFN-I), suggesting a minimised need for SARS-CoV-2 ORF6-mediated repression of IFN signalling in the presence of JQ-1. Importantly, JQ-1 exhibited a transient antiviral activity when administered prophylactically in human airway bronchial epithelial cells (hBAECs), which was gradually subverted by SARS-CoV-2, and no antiviral activity when administered therapeutically following an established infection. We propose that JQ-1 exerts pleiotropic effects that collectively induce an antiviral state in the host, which is ultimately nullified by SARS-CoV-2 infection, raising questions about the clinical suitability of the iBETs in the context of COVID-19.
- Published
- 2023
- Full Text
- View/download PDF
31. SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression.
- Author
-
Daniela Niemeyer, Saskia Stenzel, Talitha Veith, Simon Schroeder, Kirstin Friedmann, Friderike Weege, Jakob Trimpert, Julian Heinze, Anja Richter, Jenny Jansen, Jackson Emanuel, Julia Kazmierski, Fabian Pott, Lara M Jeworowski, Ruth Olmer, Mark-Christian Jaboreck, Beate Tenner, Jan Papies, Felix Walper, Marie L Schmidt, Nicolas Heinemann, Elisabeth Möncke-Buchner, Morris Baumgardt, Karen Hoffmann, Marek Widera, Tran Thi Nhu Thao, Anita Balázs, Jessica Schulze, Christin Mache, Terry C Jones, Markus Morkel, Sandra Ciesek, Leif G Hanitsch, Marcus A Mall, Andreas C Hocke, Volker Thiel, Klaus Osterrieder, Thorsten Wolff, Ulrich Martin, Victor M Corman, Marcel A Müller, Christine Goffinet, and Christian Drosten
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Epidemiological data demonstrate that Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) Alpha and Delta are more transmissible, infectious, and pathogenic than previous variants. Phenotypic properties of VOC remain understudied. Here, we provide an extensive functional study of VOC Alpha replication and cell entry phenotypes assisted by reverse genetics, mutational mapping of spike in lentiviral pseudotypes, viral and cellular gene expression studies, and infectivity stability assays in an enhanced range of cell and epithelial culture models. In almost all models, VOC Alpha spread less or equally efficiently as ancestral (B.1) SARS-CoV-2. B.1. and VOC Alpha shared similar susceptibility to serum neutralization. Despite increased relative abundance of specific sgRNAs in the context of VOC Alpha infection, immune gene expression in infected cells did not differ between VOC Alpha and B.1. However, inferior spreading and entry efficiencies of VOC Alpha corresponded to lower abundance of proteolytically cleaved spike products presumably linked to the T716I mutation. In addition, we identified a bronchial cell line, NCI-H1299, which supported 24-fold increased growth of VOC Alpha and is to our knowledge the only cell line to recapitulate the fitness advantage of VOC Alpha compared to B.1. Interestingly, also VOC Delta showed a strong (595-fold) fitness advantage over B.1 in these cells. Comparative analysis of chimeric viruses expressing VOC Alpha spike in the backbone of B.1, and vice versa, showed that the specific replication phenotype of VOC Alpha in NCI-H1299 cells is largely determined by its spike protein. Despite undetectable ACE2 protein expression in NCI-H1299 cells, CRISPR/Cas9 knock-out and antibody-mediated blocking experiments revealed that multicycle spread of B.1 and VOC Alpha required ACE2 expression. Interestingly, entry of VOC Alpha, as opposed to B.1 virions, was largely unaffected by treatment with exogenous trypsin or saliva prior to infection, suggesting enhanced resistance of VOC Alpha spike to premature proteolytic cleavage in the extracellular environment of the human respiratory tract. This property may result in delayed degradation of VOC Alpha particle infectivity in conditions typical of mucosal fluids of the upper respiratory tract that may be recapitulated in NCI-H1299 cells closer than in highly ACE2-expressing cell lines and models. Our study highlights the importance of cell model evaluation and comparison for in-depth characterization of virus variant-specific phenotypes and uncovers a fine-tuned interrelationship between VOC Alpha- and host cell-specific determinants that may underlie the increased and prolonged virus shedding detected in patients infected with VOC Alpha.
- Published
- 2022
- Full Text
- View/download PDF
32. Re-assessing the diversity of negative strand RNA viruses in insects.
- Author
-
Simon Käfer, Sofia Paraskevopoulou, Florian Zirkel, Nicolas Wieseke, Alexander Donath, Malte Petersen, Terry C Jones, Shanlin Liu, Xin Zhou, Martin Middendorf, Sandra Junglen, Bernhard Misof, and Christian Drosten
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
The spectrum of viruses in insects is important for subjects as diverse as public health, veterinary medicine, food production, and biodiversity conservation. The traditional interest in vector-borne diseases of humans and livestock has drawn the attention of virus studies to hematophagous insect species. However, these represent only a tiny fraction of the broad diversity of Hexapoda, the most speciose group of animals. Here, we systematically probed the diversity of negative strand RNA viruses in the largest and most representative collection of insect transcriptomes from samples representing all 34 extant orders of Hexapoda and 3 orders of Entognatha, as well as outgroups, altogether representing 1243 species. Based on profile hidden Markov models we detected 488 viral RNA-directed RNA polymerase (RdRp) sequences with similarity to negative strand RNA viruses. These were identified in members of 324 arthropod species. Selection for length, quality, and uniqueness left 234 sequences for analyses, showing similarity to genomes of viruses classified in Bunyavirales (n = 86), Articulavirales (n = 54), and several orders within Haploviricotina (n = 94). Coding-complete genomes or nearly-complete subgenomic assemblies were obtained in 61 cases. Based on phylogenetic topology and the availability of coding-complete genomes we estimate that at least 20 novel viral genera in seven families need to be defined, only two of them monospecific. Seven additional viral clades emerge when adding sequences from the present study to formerly monospecific lineages, potentially requiring up to seven additional genera. One long sequence may indicate a novel family. For segmented viruses, cophylogenies between genome segments were generally improved by the inclusion of viruses from the present study, suggesting that in silico misassembly of segmented genomes is rare or absent. Contrary to previous assessments, significant virus-host codivergence was identified in major phylogenetic lineages based on two different approaches of codivergence analysis in a hypotheses testing framework. In spite of these additions to the known spectrum of viruses in insects, we caution that basing taxonomic decisions on genome information alone is challenging due to technical uncertainties, such as the inability to prove integrity of complete genome assemblies of segmented viruses.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.